Reduction in overall occurrences of ischemic events with vorapaxar: Results from TRACER

Journal of the American Heart Association

Volumn 3, Issue 4, 2014, Pages

  White, Harvey D ^a   Huang, Zhen ^b   Tricoci, Pierluigi ^b   Van de Werf, Frans ^c   Wallentin, Lars ^d   Lokhnygina, Yuliya ^b   Moliterno, David J ^e   Aylward, Philip E ^f   Mahaffey, Kenneth W ^g   Armstrong, Paul W ^h  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^e UNIVERSITY OF KENTUCKY   (United States)

^f FLINDERS UNIVERSITY   (Australia)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acute coronary syndromes; Recurrent events; Vorapaxar

Indexed keywords

PLACEBO; VORAPAXAR; ANTITHROMBOCYTIC AGENT; LACTONE; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART DEATH; HEART INFARCTION; HOSPITAL READMISSION; HUMAN; INTRACARDIAC THROMBOSIS; ISCHEMIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVASCULARIZATION; ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CLINICAL TRIAL; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HUMANS; ISCHEMIA; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PYRIDINES; RECURRENCE; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME;

EID: 84939462491     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001032     Document Type: Article

References (12)

1. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404-1413.
2. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20-33.
3. TRA*CER Executive and Steering Commzrittees. The thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA*CER) trial: study design and rationale. Am Heart J. 2009;158:327-334.
4. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modelling marginal distributions. J Am Stat Assoc. 1989;84:1065-1073.
5. Janzon M, Levin LA, Swahn E. Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The Fast Revascularisation during InStability in Coronary artery disease. Eur Heart J. 2002;23:31-40.
6. Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CP. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study. Circulation. 2013;127:673-680.
7. Mahoney EM, Jurkovitz CT, Chu H, Becker ER, Culler S, Kosinski AS, Robertson DH, Alexander C, Nag S, Cook JR, Demopoulos LA, DiBattiste PM, Cannon CP, Weintraub WS. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA. 2002;288:1851-1858.
8. Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation. 2010; 121:71-79.
9. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J. 2008; 29:2473-2479.
10. Leonardi S, Tricoci P, White HD, Armstrong PW, Huang Z, Wallentin L, Aylward PE, Moliterno DJ, Van de Werf F, Chen E, Providencia L, Nordrehaug JE, Held C, Strony J, Rorick TL, Harrington RA, Mahaffey KW. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA*CER) trial. Eur Heart J. 2013;34:1723-1731.
11. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009;54:2358-2362.
12. Armstrong PW, Westerhout CM, Van de Werf F, Califf RM, Welsh RC, Wilcox RG, Bakal JA. Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. Am Heart J. 2011;161:848-854.